Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates

Liver gene therapy with adeno-associated viral (AAV) vectors delivering clotting factor transgenes into hepatocytes has shown multiyear therapeutic benefit in adults with hemophilia. However, the mostly episomal nature of AAV vectors challenges their application to young pediatric patients. We devel...

Full description

Bibliographic Details
Main Authors: Albertini, P. (Author), Annoni, A. (Author), Ayuso, E. (Author), Biffi, M. (Author), Brombin, C. (Author), Canepari, C. (Author), Cantore, A. (Author), Curto, R. (Author), Drager, D. (Author), Follenzi, A. (Author), Liu, T. (Author), Milani, M. (Author), Mueller, C. (Author), Naldini, L. (Author), Patarroyo-White, S. (Author), Plati, T. (Author), Russo, F. (Author), Visigalli, I. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items